Novavax's COVID-19 vaccine (Nuvaxovid) has been granted approval (BLA) for use in those aged 65 and older and those aged 12-64 with a condition that increases the risk of severe COVID-19 (and they will be required to conduct postmarketing studies focusing on myocarditis and pericarditis).
Comments
I hope the FDA requires monitoring for Long Covid as an endpoint.
Not doing studies for free after paying full price for the jab.
Symptoms started a few months after trial (early 2021), got Covid about six months later and I think it was more noticeable after
But I bet the risk is still lower than from a bout with live wild Covid.